Dr. Fang received his Ph.D degree in East China Normal University in Shanghai, China. He then started his research as a post-doctoral fellow in Baylor College of Medicine and focused on cancer stem cells and metastasis in triple negative breast cancer. Later on, Dr. Fang started his second post-doctoral fellowship in Dr. Xiongbin Lu’s lab at MD. Anderson Cancer Center, University of Texas., and then moved with the lab to Indiana University in 2017. His current projects are mostly focusing on immunotherapy in triple negative cancer.

Dr. Fang has published his works as first or co-first author onJournal of Clinical Investigation(2021),International Review of Cell and Molecular Biology(2017),Journal of theNational Cancer Institute(2013),Journal of medicinal chemistry(2014), andJournal of Pharmacology and Experimental Therapeutics(2011), etc. He also contributes as co-author for the papers published onNature Biomedical Engineering(2021),Archives of Biochemistry and Biophysics(2021),Journal of Clinical Investigation(2021, 2018),JCI Insight(2020),Nature Communications(2018, 2016),The FASEB Journal(2018),PLoS One(2011) andOncotarget(2015), etc.​